Last reviewed · How we verify
NCT03924479
Respiratory Muscle Function in Heart Failure
NA trial testing PowerBreathe (Breathing muscle training) in Heart Failure, Diastolic in 30 participants. Completed in 21 March 2024.
21 March 2024
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 30 |
| Start date | 28 November 2018 |
| Primary completion | 21 March 2024 |
| Estimated completion | 21 March 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- PowerBreathe (Breathing muscle training)
Conditions studied
- Heart Failure, Diastolic — all drugs for Heart Failure, Diastolic →
Sponsor
Mayo Clinic
Who can join
21 and older, any sex, with Heart Failure, Diastolic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is being done because investigators are trying to determine how respiratory muscle and lung function influence the exercise responses in heart failure and healthy participants. Further, the heart failure patients will participate in an intervention to improve their respiratory muscle function to determine if this improves exercise capacity.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Nonpharmacological Strategies in Heart Failure with Preserved Ejection Fraction.
Bohmke NJ, Billingsley HE, Kirkman DL, Carbone S. · · 2022 · cited 8× · PMID 36210133 · DOI 10.1016/j.ccl.2022.06.003
Verify or expand the search:
- PubMed search for NCT03924479
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure, Diastolic
Currently open trials in the same condition.
- NCT07199088 — Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Ac · NA · recruiting
- NCT05887271 — A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejec · Phase 2, PHASE3 · recruiting
- NCT05989945 — HIDRAdenitis Suppurativa and HEART Disease · active not recruiting
- NCT05752760 — Pilot Study Lp299v Supplementation in Chronic Heart Failure · NA · recruiting
- NCT06084468 — Cardiac Structure and Function in Patients with Cystic Fibrosis · active not recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03924479 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 22 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03924479.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing